Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration

4 Jan 2022

Abstract excerpt

Background: The human gut microbiota are important to health and wellness, and disrupted microbiota homeostasis, or “dysbiosis,” can cause or contribute to many gastrointestinal disease states. Dysbiosis can be caused by many factors, most notably antibiotic treatment. To correct dysbiosis and restore healthier microbiota, several investigational microbiota-based live biotherapeutic products (LBPs) are in formal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Gastrointestinal motility and disorders
Share to Gut microbiota and health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35058900
DOI: 10.3389/fmicb.2021.781275

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent RestorationPMID 35058900Read ↗

Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection PreventionSemantic proximity Read ↗

Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challengesSemantic proximity Read ↗

Antibiotic Treatments for Clostridium difficile Infection Are Associated with Distinct Bacterial and Fungal Community StructuresSemantic proximity Read ↗

A randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health associated taxaSemantic proximity Read ↗

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trialSemantic proximity Read ↗

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trialSemantic proximity Read ↗

Advances in Lactobacillus Restoration for β-Lactam Antibiotic-Induced Dysbiosis: A System Review in Intestinal Microbiota and Immune HomeostasisSemantic proximity Read ↗

The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trialSemantic proximity Read ↗

Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19Semantic proximity Read ↗

Intestinal IgA-Coated Bacteria in Healthy- and Altered-Microbiomes (Dysbiosis) and Predictive Value in Successful Fecal Microbiota TransplantationSemantic proximity Read ↗

Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adultsSemantic proximity Read ↗

A rational approach for the targeted discovery and characterisation of microbiome-derived therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.